Endometriosis
Endometriosis is a complex and debilitating condition that affects millions of women worldwide. At our company, we are dedicated to advancing endometriosis drug and therapy development through our comprehensive range of services.
Overview of Endometriosis
Endometriosis, an enduring inflammatory condition, manifests as the presence of endometrial-like tissue outside its usual location in the uterus. This aberrant tissue can implant and proliferate on various pelvic organs, including the ovaries, fallopian tubes, and pelvic lining. Retrograde menstruation, where menstrual blood flows backward into the pelvic cavity, is considered a significant contributing factor, facilitating the implantation and growth of endometrial tissue in ectopic sites. Hormonal imbalances, particularly an excess of estrogen, play a role in the growth and persistence of endometriotic lesions. Furthermore, inflammation and angiogenesis are pivotal processes in the development and perpetuation of endometriosis, further fueling the progression of this condition.
Fig.1 Factors that cause endometriosis. (Saunders P. T., et al., 2021)
Therapy Discovery and Development for Endometriosis
Endometriosis drugs and therapies aim to alleviate pain, reduce inflammation, and address fertility issues associated with the condition. The table below shows examples of potential endometriosis therapies that have shown positive responses in mouse models of endometriosis.
| Drug type/name | Target protein | Model | Results |
|---|---|---|---|
| inhibitor/DCA | PDK | mouse (i.p. injection menses-mimic) | reduced lesion size |
| antagonist/JNJ17203212 | TRPV1 | mouse (i.p. injection menses-mimic) | no impact on evoked abdominal pain |
| antibody/A10-1C04 | IL-33 | mouse (i.p. injection minced uterus) | reduced volume of lesions |
| inhibitor/linsitinib | IL-1ßR | mouse (i.p. injection menses-mimic) | reduced neuronal growth, abrogated spontaneous pain behaviors |
| antagonist/CGRP8-37 | RAMP-1 (CGRP receptor) | mouse, ectopic endometrial transplant model | inhibition of lesion growth/angiogenesis |
| THC (natural agonist) | CB1/2 | mouse (suture onto peritoneal wall) | reduced cyst formation, abrogated pain and anxiety behaviors |
Our Services
With an exceptional team of accomplished researchers and scientists, our company is dedicated to develop innovative endometriosis therapeutic solutions. To delve deeper into the comprehensive offerings we provide, we invite you to click on the link below.
To meet the enormous challenges of developing endometriosis therapies, our company offers comprehensive preclinical research services. Through a combination of in vitro and in vivo studies, we assess the efficacy and mechanism of action of potential therapeutic interventions. Our team of experts analyzes and interprets the data generated from preclinical studies, providing comprehensive reports that guide decision-making in the drug development process.
Transgenic Mouse Models
Transgenic mouse models play a pivotal role in understanding the molecular mechanisms underlying endometriosis. We offer expertise in developing and utilizing transgenic mouse models that express luciferase, enabling researchers to correlate lesion size with emitted light.
Xenotransplantation Mouse Models
Our team has extensive experience in utilizing immunodeficient mouse models, including athymic nude, SCID, and NOD-SCID mice, for xenotransplantation of human endometrium. These models allow for the investigation of human endometrial responses to potential therapies in an in vivo setting.
Non-human Primate Models
Rhesus monkeys and baboons, among other non-human primates, exhibit similarities in reproductive physiology and anatomy, making them excellent models for studying endometriosis. We have extensive experience in developing non-human primate animal models of endometriosis.
In Vitro Models
Our cell-based model development services include primary endometrial cell culture and co-culture systems. Moreover, by culturing endometrial stem cells or endometrial tissue fragments, we can generate organoids that consist of multiple cell types, including epithelial cells and immune cells.
We collaborate closely with our clients, offering valuable insights and recommendations for further development. Beyond the wide range of services and models mentioned previously, our expertise extends to crafting bespoke solutions and designing disease models that are perfectly tailored to your individual requirements. We take great pride in our ability to adapt and customize our offerings to meet the unique needs of each client. If our comprehensive range of services has piqued your interest, we wholeheartedly encourage you to contact us without any hesitation.
References
- Saunders Philippa TK, and Andrew W. Horne. "Endometriosis: Etiology, pathobiology, and therapeutic prospects." Cell 184.11 (2021): 2807-2824.
- Wang Yeh, Kristen Nicholes, and Ie-Ming Shih. "The origin and pathogenesis of endometriosis." Annual Review of Pathology: Mechanisms of Disease 15 (2020): 71-95.